B&K Corp Ltd

02396

Company Profile

  • Business description

    B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products.

  • Contact

    No. 19 Qinling Road, Xiexin Center
    Room 1507, Building 1
    Laoshan District
    Shandong Province
    Qingdao
    CHN

    http://www.huarenshengwu.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

Stocks News & Analysis

stocks

This ASX miner is the cheapest in our iron ore coverage

High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks

Apple names new CEO as Tim Cook steps aside after 15 years

John Ternus, Apple’s hardware chief, will take up the role in September.
stocks

Updating our commodity price assumptions

Our view as China’s steel production drops.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,074.4050.80-0.56%
CAC 408,156.4379.28-0.96%
DAX 4024,194.9075.97-0.31%
Dow JONES (US)49,419.13269.750.55%
FTSE 10010,476.4621.63-0.21%
HKSE26,163.24324.24-1.22%
NASDAQ24,616.41356.441.47%
Nikkei 22559,585.86236.690.40%
NZX 50 Index12,945.6013.270.10%
S&P 5007,127.5863.570.90%
S&P/ASX 2008,843.6053.20-0.60%
SSE Composite Index4,106.2621.180.52%

Market Movers